Profound Medical Q3 EPS $(0.26) Beats $(0.34) Estimate, Sales $1.73M Miss $2.06M Estimate
Portfolio Pulse from bharat@benzinga.com
Profound Medical reported Q3 losses of $(0.26) per share, beating the analyst consensus estimate of $(0.34) by 23.53%. However, the company's quarterly sales of $1.73 million missed the analyst consensus estimate of $2.06 million by 16.12%. This represents a 15.09% decrease over sales from the same period last year.
November 02, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Profound Medical's Q3 earnings beat estimates but sales missed, indicating mixed performance.
Profound Medical's earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100